TABLE 3.
Fasted arterialized metabolites before (pre) and after (post) 2 wk of eTRF or CON:CR1
| Characteristic | Pre-CON:CR | Pre-eTRF | Post-CON:CR | Post-eTRF |
|---|---|---|---|---|
| Glucose, mmol·L−1 | 4.13 ± 0.09 | 4.03 ± 0.08 | 4.00 ± 0.13 | 4.08 ± 0.17 |
| Serum insulin, ρmol·L−1 | 37 ± 5** | 74 ± 12 | 43 ± 5 | 63 ± 7 |
| Serum TAG, mmol·L−1 | 0.72 ± 0.10 | 0.81 ± 0.12 | 0.73 ± 0.10 | 0.73 ± 0.09 |
| Plasma FFA, mmol·L−1 | 0.54 ± 0.04 | 0.51 ± 0.09 | 0.58 ± 0.09 | 0.58 ± 0.06 |
| Plasma BCAA, μmol·L−1 | 207 ± 20 | 263 ± 18 | 222 ± 21 | 257 ± 23 |
| Plasma total ghrelin, ρmol·L−1 | 229 ± 19 | 282 ± 15 | 203 ± 21** | 281 ± 15 |
1Data are means ± SEMs; n = 8 per group. Mixed-design 2-factor ANOVA revealed an intervention (group) effect (P = 0.01) for both insulin and ghrelin (post hoc **P = 0.01 from corresponding eTRF time point). BCAA, branched-chain amino acid; CON:CR, control/caloric restriction; eTRF, early time-restricted feeding; FFA, free fatty acid; TAG, triglyceride.